Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;22(8):1118-1119.
doi: 10.1016/S1473-3099(22)00427-3. Epub 2022 Jun 28.

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people

Santiago Oviedo Rouco  1 , Pamela E Rodriguez  1 , Esteban A Miglietta  1 , Pablo Rall  2 , María M Gonzalez Lopez Ledesma  1 , Augusto Varese  3 , Carla A Pascuale  1 , Diego S Ojeda  1 , Bianca Mazzitelli  3 , Lautaro Sanchez  1 , Ana Ceballos  3 , Eduardo Perez  2 , Jorge Geffner  3 , Yanina Miragaya  2 , Andrés H Rossi  1 , Andrea V Gamarnik  4
Affiliations

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people

Santiago Oviedo Rouco et al. Lancet Infect Dis. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. SOR, PER, EAM, PR, and MMGLL contributed equally.

Figures

Figure
Figure
Humoral response over time after two-dose scheme with BBIBP-CorV and heterologous booster with ChAdOx1 nCoV-19, Sputnik V, or BNT162b2 IgG anti-spike antibody concentrations are quantified according to the WHO International Antibody Standard. Antibodies were measured at days 21, 100, 160, and 220 after primary immunisation in 26 participants and at days 21 and 90 after a booster dose in 98 participants. 27 volunteers received ChAdOx1 nCoV-19, 38 volunteers received Sputnik V, and 33 volunteers received BNT162b2. Geometric means with 95% CIs are indicated. Circles indicate individual participants. The Mann-Whitney U test was used. BAU=binding antibody units. *p=0·0003. †p<0·0001.
See this image and copyright information in PMC

References

    1. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22:1002–1010. - PMC - PubMed
    1. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399:521–529. - PMC - PubMed
    1. Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, et al. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog. 2021;17 - PMC - PubMed
    1. Sanchez L, Oviedo Rouco S, Pifano M, et al. Antibody durability at 1 year after Sputnik V vaccination. Lancet Infect Dis. 2022;22:589–590. - PMC - PubMed

Publication types

LinkOut - more resources